CorVel Corporation

CorVel Corporation (CRVL) Market Cap

CorVel Corporation has a market capitalization of $3.03B.

Price: $59.87

0.65 (1.09%)

Market Cap: 3.03B

NASDAQ · time unavailable

CEO: Michael G. Combs

Sector: Financial Services

Industry: Insurance - Brokers

IPO Date: 1991-06-28

Website: https://www.corvel.com

CorVel Corporation (CRVL) - Company Information

Market Cap: 3.03B|Sector: Financial Services

Company Profile

CorVel Corporation provides workers' compensation, auto, liability, and health solutions for employers, third party administrators, insurance companies, and government agencies to assist them in managing the medical costs and monitoring the quality of care associated with healthcare claims. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement services, retrospective utilization review, facility claim review, professional review, pharmacy services, directed care services, Medicare solutions, clearinghouse services, independent medical examinations, and inpatient medical bill review. It also provides a range of patient management services, such as claims management, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, and life care planning, as well as processing of claims for self-insured payors with respect to property and casualty insurance. The company was incorporated in 1987 and is headquartered in Fort Worth, Texas.

Analyst Sentiment

50%
Hold

From 0 Active Polls

Consensus Target Matrix

Data feed parsing pending...

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$62.86
▲ +5.00% Upside
Low Target
$44.90
-25% Risk
Median Target
$61.06
2% Mid
High Target
$74.83
25% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)3,0352,7953,4813,9735,2785,7545,7175,6004,316
Enterprise Value ($M)2,8222,5833,2953,8105,1035,6115,5845,4944,215
Price to Earnings Ratio (P/E)27.7522.5235.9935.5948.4554.4560.1359.8450.01
Price/Earnings-to-Growth Ratio (PEG)4.1116.9435.0835.0537.5510.0123.09
Price to Sales Ratio (P/S)3.1711.2514.7716.5822.4924.8525.0824.9620.39
Price to Book Ratio (P/B)7.777.099.2610.9515.4117.8719.0019.8116.36
Price to Free Cash Flow Ratio (P/FCF)27.52137.7598.96260.15133.46403.50178.05450.85131.73
Enterprise Value to Sales (EV/Sales)10.3913.9815.9021.7424.2424.4924.4819.91
Enterprise Value to EBITDA (EV/EBITDA)16.9665.0482.2287.09119.04137.13145.81151.00121.25
Debt to Equity Ratio-1.280.050.120.120.080.090.100.110.12

CRVL Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$59.87
Intrinsic Value$48.33
Market Alignment
Overvalued by 19.3%relative to calculated intrinsic value
9.00%
Exp: 5%5%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2036)

Terminal FCF Base$0.16B
Perpetuity TV Value$2.98B
Discounted TV (PV)$1.15B
TV Weighting %57.7%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CORVEL CORP (CRVL) — Investment Overview

🧩 Business Model Overview

CorVel operates in the workers’ compensation and disability/health cost-management value chain, providing outsourced services that help payors and employers control claim costs while improving outcomes and care coordination. The workflow typically starts with claim intake and ongoing claim adjudication support, then extends into clinical and administrative interventions such as utilization management, medical bill review, case and disability management, and return-to-work services. The business is structured around managing medically driven claim complexity—where administrative efficiency and clinical governance materially affect total cost of claims.

A key feature of CorVel’s model is that services are delivered through an operational system: consistent processes, embedded clinical and administrative expertise, and claim-level data captured across the life of a claim. That combination supports repeatable execution for customers who outsource claims oversight and medical cost containment rather than building these capabilities internally.

💰 Revenue Streams & Monetisation Model

CorVel monetizes primarily through contracted, service-based fees tied to claim activity and service delivery. Revenue is generally composed of:

  • Administrative/claims-service fees (often structured per claim, per member, or per specific service activity under contract terms).
  • Medical cost containment services such as medical bill review and utilization management, where fees are driven by claim volume and the breadth of services deployed.
  • Disability and return-to-work services that monetize ongoing case management activity and care-navigation steps that influence duration and outcomes.

Margin drivers are less about one-time project work and more about operating leverage: scaling staff productivity and workflow efficiency, leveraging established provider relationships, and applying standardized clinical/administrative controls across a large claims footprint. Because medical cost containment can materially influence total claim outcomes, contract renewals and expansions tend to reinforce recurring revenue visibility.

🧠 Competitive Advantages & Market Positioning

CorVel’s durability is best understood through switching costs and operational/clinical know-how, both of which are difficult to replicate quickly by new entrants or generalist TPAs.

  • High switching costs (data gravity + process integration): Claim handling is operationally embedded—customers integrate systems, workflows, and decision policies. Once a vendor is running utilization review, bill review, and case management, migrating an active or historically heavy claims program increases disruption risk and timeline costs.
  • Clinical and administrative compliance expertise: Workers’ compensation and healthcare-adjacent workflows are heavily rule-driven across jurisdictions. Competitors must demonstrate disciplined execution and measurable outcomes while maintaining compliance.
  • Provider and network relationships: Effective care coordination and utilization governance depend on relationships and practical familiarity with provider behaviors and local care patterns.

Competitive benchmarking:

  • Sedgwick: A large, broad claims administration platform. CorVel differentiates through a more concentrated emphasis on medical cost containment and disability/return-to-work management embedded within a structured claims workflow.
  • Gallagher Bassett: A major claims administrator with wide service breadth. CorVel’s positioning emphasizes specialized service delivery and operational integration around medical management controls.
  • Crawford & Company: Another leading adjuster/claims services provider. CorVel contrasts by focusing on the medical management stack (utilization and bill review-style services) and the operational mechanisms that reduce medically driven leakage.

Overall, CorVel competes less on scale alone and more on repeatable execution in medically complex claim pathways—creating sticky customer relationships where switching is costly and outcomes are monitored.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, CorVel’s addressable opportunity is supported by secular and operational trends that increase outsourcing demand and raise the value of disciplined medical cost governance:

  • Medical cost containment remains structurally important: Even when labor markets fluctuate, medical utilization and provider pricing dynamics persist, keeping cost-management services in demand.
  • Shift toward outsourced expertise: Employers and carriers increasingly favor specialist vendors for utilization management, bill review, and disability/return-to-work services rather than building internal capabilities.
  • Increased claim complexity: Higher chronic-condition prevalence, evolving treatment patterns, and greater administrative burdens increase the value of coordinated case management and utilization oversight.
  • Service expansion within existing accounts: Vendors with integrated systems can expand share of wallet by adding adjacent service lines (e.g., deeper utilization governance alongside case management).
  • Technology-enabled efficiency: While technology is not a moat by itself, operational analytics and workflow automation can support productivity and consistent application of clinical and administrative controls at scale.

⚠ Risk Factors to Monitor

  • Regulatory and jurisdictional variability: Workers’ compensation and healthcare-adjacent rules vary by state and can affect utilization protocols, documentation requirements, and allowable processes.
  • Medical trend and utilization shifts: Changes in treatment intensity, provider billing patterns, or utilization behavior can pressure outcomes and cost savings if not offset by operational controls.
  • Contracting and competitive dynamics: Larger TPAs may bundle services aggressively, and pricing pressure can influence margins if contract renewals deteriorate.
  • Service quality and governance risk: Because services are operationally embedded in claim outcomes, execution errors or inconsistent decisioning can increase disputes, rework, or customer churn.
  • Data security and privacy: Claim and health-adjacent data requires robust security and compliance; any material breach would impact customer trust and regulatory exposure.

📊 Valuation & Market View

The market generally values CorVel-like service businesses on cash-generation and operating performance, typically through EV/EBITDA or similar earnings-based frameworks, with contract quality and margin stability influencing the multiple. Where investors apply revenue-multiple thinking, it is often connected to perceived durability and recurrence of service fees.

Key valuation drivers include:

  • Renewal and retention rates (evidence of sticky switching-cost economics).
  • Operating leverage from scaled workflows and case-processing productivity.
  • Execution on cost containment outcomes that support customer confidence and expansion.
  • Stability of volumes and the ability to manage medically driven variability in utilization.

🔍 Investment Takeaway

CorVel’s investment case rests on structural stickiness created by integrated claim workflows and data/process integration, supported by specialized clinical and administrative capabilities in workers’ compensation medical cost management. The company is positioned to benefit from persistent demand for outsourced utilization governance, bill review-style cost containment, and disability/return-to-work coordination—areas where switching costs and execution quality matter more than raw scale.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CRVL.

globenewswire.com2026-06-02

CorVel Marks 35 Years on Nasdaq, Signals Next Phase of Long-Term Innovation and Growth

FORT WORTH, Texas, June 02, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced that it will mark its 35th anniversary as a publicly traded company listed on the Nasdaq Stock Market. Members of the company's executive leadership team, including Chairman, President, and CEO Michael Combs, will commemorate the milestone by ringing the Nasdaq opening bell in New York City.

globenewswire.com2026-06-01

CorVel Appoints Sarah Scott CEO and President; Michael G. Combs to Transition to Executive Chair

FORT WORTH, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- CorVel today announced that Sarah Scott will be appointed CEO and President, effective July 1, 2026, succeeding Michael G. Combs, who will transition to the role of Executive Chair.

marketbeat.com2026-05-20

CorVel Q4 Earnings Call Highlights

CorVel NASDAQ: CRVL said revenue and earnings increased in its March quarter and fiscal 2026, as growth in its Network Solutions business, stronger bookings and operating efficiency helped offset a higher effective tax rate.

seekingalpha.com2026-05-20

CorVel Corporation (CRVL) Q4 2026 Earnings Call Transcript

CorVel Corporation (CRVL) Q4 2026 Earnings Call Transcript

globenewswire.com2026-05-20

CorVel Announces Revenues and Earnings

FORT WORTH, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter and fiscal year ended March 31, 2026. Revenues for the fiscal year ended March 31, 2026 were $959 million, a 7% increase from $896 million during the fiscal year ended March 31, 2025. Earnings per share for the fiscal year ended March 31, 2026 were $2.14, up 17% compared to $1.83 during the fiscal year ended March 31, 2025. Revenues for the quarter were $249 million, an increase from $232 million in the March quarter of 2025. Earnings per share for the quarter were $0.61, up 20% compared to $0.51 in the same quarter of the prior year.

globenewswire.com2026-05-12

CorVel Corporation to Host Live Earnings Release Webcast

FORT WORTH, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), a leading provider of innovative risk management solutions, is pleased to announce that it will host a live webcast to discuss its upcoming quarterly and fiscal earnings results on Wednesday, May 20, 2026, at 11:30 AM Eastern Time. The webcast will feature a discussion of CorVel's financial performance, strategic initiatives, and outlook, led by Michael Combs, President and Chief Executive Officer, alongside Brian Nichols, Chief Financial Officer.

globenewswire.com2026-04-29

CorVel Corporation Launches CorVel Connected™, an AI-Powered Claims Intelligence Layer Embedded in CareMC®

CorVel launches CorVel Connected, an AI‑powered intelligence layer in CareMC that embeds decision support into claim workflows to improve speed, outcomes.

defenseworld.net2026-04-25

Evergreen Capital Management LLC Acquires New Shares in CorVel Corp. $CRVL

Evergreen Capital Management LLC acquired a new position in shares of CorVel Corp. (NASDAQ: CRVL) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 11,584 shares of the business services provider's stock, valued at approximately $784,000. Other hedge funds and other institutional investors also

defenseworld.net2026-04-16

CorVel (NASDAQ:CRVL) Share Price Passes Below 200-Day Moving Average – Here’s What Happened

CorVel Corp. (NASDAQ: CRVL - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $64.53 and traded as low as $54.71. CorVel shares last traded at $55.96, with a volume of 161,331 shares traded. Analyst Ratings Changes

defenseworld.net2026-03-31

CorVel (NASDAQ:CRVL) Share Price Crosses Below 200-Day Moving Average – What’s Next?

CorVel Corp. (NASDAQ: CRVL - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $66.65 and traded as low as $53.09. CorVel shares last traded at $54.22, with a volume of 212,502 shares traded. Analyst Ratings Changes

fool.com2026-03-25

CorVel Insider Sale of $130K Comes Amid 50% One-Year Stock Drop. Here's What Investors Should Know

The chief information officer of Cervel reported selling 2,400 shares for a total of $130,000, based on a weighted average price of $54.00 per share on March 16, 2026. The entire transaction involved direct holdings via option exercise and immediate sale; no indirect entities were involved.

defenseworld.net2026-03-15

Algert Global LLC Purchases 92,077 Shares of CorVel Corp. $CRVL

Algert Global LLC increased its position in shares of CorVel Corp. (NASDAQ: CRVL) by 73.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 217,559 shares of the business services provider's stock after acquiring an additional 92,077 shares during the quarter.

seekingalpha.com2026-02-21

CorVel: Margin-Driven Upside After Growth Reset

CorVel: Margin-Driven Upside After Growth Reset

globenewswire.com2026-02-17

CorVel Earns Sixth Consecutive Great Place To Work® Certification™, Reflecting Continued Investment in Employees and Innovation

FORT WORTH, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) is proud to be Certified™ by Great Place To Work® for the sixth consecutive year, an honor based entirely on employee feedback regarding their experience working at CorVel. The certification reflects the company's focus on creating a workplace where employees feel supported, empowered, and equipped to do their best work.

seekingalpha.com2026-02-03

CorVel Corporation (CRVL) Q3 2026 Earnings Call Transcript

CorVel Corporation (CRVL) Q3 2026 Earnings Call Transcript

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"CRVL reported Q4’26 (ended 2026-03-31) revenue of $248.5M and net income of $31.0M (EPS: $0.61). QoQ, revenue rose from $235.6M in 2025-12-31 (+5.5%) and net income increased from $24.2M (+28.3%). YoY, revenue grew from $231.5M (2025-03-31) (+7.4%) and net income increased from $26.4M (+17.5%), with EPS up similarly (0.51 to 0.61, +19.6% YoY). Profitability improved across the quarter: gross margin expanded to 25.35% from 23.31% QoQ, while net margin improved to 12.48% from 10.26% QoQ. Operating income and operating margin also improved, with operating margin rising to 15.98% from 13.68% QoQ. Cash flow quality looks strong on a quarterly basis: operating cash flow was $155.5M and free cash flow was $110.2M, supporting a net cash position (net debt: -$212.4M) and rising cash balances. From a shareholder-return perspective, CRVL’s stock price at $55.98 is down sharply over 1Y (-52.2%), so capital appreciation has been negative despite improvements in fundamentals. No dividends are paid, and buybacks appear modest versus cash generation in this quarter."

Revenue Growth

Positive

Revenue grew +5.5% QoQ (235.6M to 248.5M) and +7.4% YoY (231.5M to 248.5M), indicating steady expansion.

Profitability

Good

Net income increased +28.3% QoQ and +17.5% YoY. Margins improved: net margin to 12.48% from 10.26% QoQ; gross margin to 25.35% from 23.31% QoQ.

Cash Flow Quality

Good

Operating cash flow was $155.5M with free cash flow of $110.2M in the quarter. Net cash position is strong (net debt -$212.4M) and dividends are zero; buybacks were limited.

Leverage & Balance Sheet

Positive

Balance sheet shows resilience: total assets $643.0M, equity $394.2M, and net cash (net debt -$212.4M). Leverage remains low.

Shareholder Returns

Neutral

Total shareholder return is pressured by price action: 1Y stock change is -52.2%. With no dividend yield and only modest repurchases, returns have been negative.

Analyst Sentiment & Valuation

Fair

Valuation indicators are elevated (e.g., price/earnings shown as 22.5x in the latest ratio set), and there is no stated price target in the dataset; sentiment appears weak given the -52.2% 1Y move.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

So what: CorVel delivered steady top-line growth (+7% revenue, +17% EPS) with margin expansion and disciplined capital deployment. Q4 showed improved operating efficiency as G&A declined as a share of revenue (10.6% to 9.4%), and fiscal 2026 operating margin rose to 15% (+1.4%). EPS growth was partially tempered by an elevated effective tax rate versus the prior year’s non-recurring stock-option discrete benefit, but other positives offset it, including lower G&A and Network Solutions momentum. The key forward driver is CERIS/CORVEL Connected scaling: management highlighted 56% YoY bookings growth, a 20% RFP increase, and 2026 pipeline conversion into four large payer programs, including two new multiyear partnerships with top-10 national payers. Prepaid-focused work is expected to shorten revenue realization (1–2 months vs 6+ months for postpaid) while maintaining margin profile. With net debt not mentioned beyond “debt-free” and $233M cash, the company appears well funded to invest in AI/automation and implementation capacity, though one-time CERIS timing and partner/provider/regulatory constraints remain watch items.

AI IconGrowth Catalysts

  • Network Solutions: accelerated post-payment recoveries tied to large payer engagement; timing-related tailwind expected to scale
  • New multiyear large payer programs launching in 2026 (4 total; 2 new top-10 national payer partnerships) expected to drive back-half calendar-year revenue/profit as implementations mature
  • Patient management: low single-digit revenue/profit growth supported by operational efficiency and continued service quality investments
  • Automation and AI-enabled workflow enhancements expected to reduce manual reliance and improve operating leverage through remainder of year and into 2027
  • CERIS shift toward proactive payment accuracy (prepay/postpay integrated) supporting a shorter revenue realization cycle for prepaid

Business Development

  • CERIS: 2 new multiyear partnerships with top 10 national payers (within 4 large payer programs launching in 2026)
  • Large payer wins driving accelerated post-payment recoveries (named payers not provided)

AI IconFinancial Highlights

  • March quarter revenue: $249M, +7% YoY vs $232M
  • March quarter EPS: $0.61, up from $0.51 YoY
  • Fiscal 2026 revenue: $959M, +7% YoY vs $896M
  • Fiscal 2026 EPS: $2.14, +17% vs $1.83
  • Effective tax rate increased vs prior year due to non-recurring discrete stock-option-exercise benefit in prior year; tax increase tempered earnings growth
  • Fiscal year Network Solutions: certain one-time events in CERIS added $0.02 to EPS (timing-related benefit from accelerated post-payment recoveries)
  • Q4 G&A: decreased $1.3M YoY; G&A as % of revenue improved from 10.6% to 9.4%
  • Fiscal year operating margin: 15%, +1.4% (percentage-point improvement) vs 2025

AI IconCapital Funding

  • Share repurchases (fiscal 2026): 872,744 shares for $56M; 366,306 shares repurchased in Q4 for $20M
  • Total repurchase program: 115.3M shares repurchased for $868M since inception
  • Program coverage: repurchased 69% of total shares outstanding at average price $7.70
  • Balance sheet: debt-free; cash balance $233M at fiscal year-end
  • Operating cash flow funded repurchases; free cash flow $66M (+$7M vs fiscal 2025)

AI IconStrategy & Ops

  • Technology investment: AI and automation to enhance accuracy, throughput, and reduce manual processes; AI focused on augmenting teams via workflow automation/predictive insights/next-best-action guidance
  • CorVel Connected: unified claims/clinical/pharmacy/network data in real time; aims to rearchitect claim decisioning around actionable intelligence
  • Connected interface positioning: earlier risk identification, faster access to care, and decision support across the claim continuum
  • Operational initiatives: clinically driven utilization management, expanded telemedicine, and bundled/episode-based care models to manage medical/pharmacy spend
  • Implementation/process efficiency: personnel levels increased for near-term execution and are expected to normalize as deployments mature and automation/AI roll out
  • Connectivity/compliance: investment in automation, API-driven connectivity, and compliance infrastructure to enable real-time data exchange and reduce friction

AI IconMarket Outlook

  • 2026: launching 4 large payer programs, including 2 new multiyear partnerships with top 10 national payers
  • Revenue realization cycle: prepaid typically 1–2 months vs 6 months or longer for postpaid; management expects comparable margin profiles
  • Bookings: March quarter new bookings +56% YoY; RFP activity +20% YoY; multiyear bookings expected to contribute meaningfully to revenue and profit growth in back half of calendar 2026

AI IconRisks & Headwinds

  • Higher effective tax rate in fiscal 2026 due to non-recurring discrete benefit in prior year (stock option exercise) potentially limiting earnings comp
  • One-time events in CERIS contributed to elevated revenue/profit; future results may not replicate timing-related uplift
  • Labor constraints remain a challenge, requiring continued automation/AI deployment to sustain productivity and operating leverage
  • Claims environment: rising claims severity and medical cost complexity (aging workforce, comorbidities, behavioral health expansion) increases delivery and cost-control difficulty
  • Provider access constraints and regulatory complexity for partners could slow adoption/implementation timelines
  • Cyber/operational risk dynamics from faster AI-driven vulnerability discovery and exploitation; requires ongoing governance, controls, and resilience investment

Q&A: Analyst Interest

    Sentiment: MIXED

    Note: This summary was synthesized by AI from the CRVL Q4 2026 (March quarter; fiscal year ended March 31, 2026) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

    📋 Official Regulatory 10-K / 10-Q SEC Filings

    Direct authenticated documentation links to audited SEC database reports for CRVL.

    SEC EDGAR Live Feed
    Loading financial data and tables...
    📁

    SEC Filings (CRVL)

    © 2026 Stock Market Info — CorVel Corporation (CRVL) Financial Profile